ClinicalTrials.gg
CompletedNCT02201199Updated Dec 24, 2014

Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus

A Phase 1 interventional study of insulin glargine U200 HOE901 and insulin glargine U500 HOE901 in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-24.

Sponsored by Sanofi · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 10 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.

Enrollment
43rd of 60
36 · median 86
Started
2014
with 1 other
Phase 1
20 of 67
none open now
Registered
34th of 67
by date

Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 43rd largest by enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2014, is one of 20 in phase 1, and was the 34th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Diabetes Mellitus, Type 1 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To compare the pharmacokinetic (PK) characteristics of single doses of insulin glargine given as U200 and U500 with those of a single dose (SD) of Lantus® U100 in a euglycemic clamp setting in subjects with type 1 diabetes.

Secondary Objectives:

To compare the metabolic activity characteristics of single doses of insulin glargine given as U200 and U500 with those of a single dose of Lantus® U100 in a euglycemic clamp setting in subjects with type 1 diabetes.

To assess the safety and tolerability of single doses of U200, U500 and Lantus® U100 in subjects with type 1 diabetes.

Read the detailed description

Total study duration for each subject is between 3.5 and 12 weeks.

Two overnight stays at the unit in each of 3 treatment periods.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, between 18 and 65 years of age, inclusive, with type 1 diabetes mellitus for more than one year, as defined by the American Diabetes Association.
  • Total insulin dose \<1.2 U/kg/day.
  • Minimum usual basal insulin dose ≥0.2 U/kg/day.
  • Body weight between 50.0 kg and 110.0 kg, between 18.5 and 30.0 kg/m2 inclusive.
  • Fasting negative serum C-peptide (\<0.3 nmol/L).
  • Glycohemoglobin () ≤75 mmol/mol (≤9.0%).
  • Stable insulin regimen for at least 2 months prior to inclusion in study.
  • Certified as otherwise healthy for Type 1 diabetes mellitus patient.
  • Women of with negative pregnancy test and use of a highly effective method or women with confirmed status.
  • Having given written prior to undertaking any study-related procedure.

Exclusion criteria

Exclusion criteria:

  • More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months.
  • Frequent severe headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month).
  • Presence or history of a drug allergy or allergic disease according to the Investigator's judgment.
  • Presence or history of drug or alcohol abuse (alcohol consumption >40 grams / day).
  • Smoking more than 5 cigarettes or equivalent per day, unable to refrain from smoking.
  • Any medication (including St John's Wort) within 14 days before inclusion, or within 5 times the elimination half-life or pharmacodynamic half-life of that drug, whichever the longest and regular use of any medication in the last month before study start with the exception of insulin products, thyroid hormones, lipid-lowering and antihypertensive drugs, and, if female, with the exception of hormonal or menopausal hormone replacement therapy; any vaccination within the last 28 days; any biologics (antibody or its derivatives) given within 4 months before randomization.
  • Known to insulin glargine or of the study drug.
  • Any history or presence of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in first degree relatives (parents, siblings or children).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    insulin glargine U100

    1 single dose

    Drug: insulin glargine U100 HOE901

  • Experimental
    insulin glargine U200

    1 single dose

    Drug: insulin glargine U200 HOE901

  • Experimental
    insulin glargine U500

    1 single dose

    Drug: insulin glargine U500 HOE901

Interventions

  • Druginsulin glargine U200 HOE901

    Pharmaceutical form:solution for injection Route of administration: subcutaneous

  • Druginsulin glargine U500 HOE901

    Pharmaceutical form:solution for injection Route of administration: subcutaneous

  • Pharmaceutical form:solution for injection Route of administration: subcutaneous

    Also known as: Lantus

06

What researchers measure

Primary outcomes

  1. Area under the serum insulin glargine (INS) concentration curve over the first 12 hours after dosing

    Time frame: 12 hours

Secondary outcomes

  1. INS-Area Under the Curve (AUC) over 24 and 36 hours after dosing (INS AUC 0-24 and INS AUC 0-36)

    Time frame: 36 hours

  2. AUC up to the last measurable concentration

    Time frame: 36 hours

  3. Time to reach 50% of INS-AUC 0-36

    Time frame: 36 hours

  4. Time to reach INS-Cmax (INS-tmax)

    Time frame: 36 hours

  5. Area under the body-weight-standardized Glucose Infusion Rate (GIR) over the first 12, 24 and 36 hours after dosing (GIR-AUC0-12, GIR-AUC0-24 and, GIR-AUC0-36)

    Time frame: 36 hours

  6. Time to reach 50% of GIR-AUC0-36 (T50%-GIR-AUC0-36)

    Time frame: 36 hours

  7. Maximum smoothed body weight standardized glucose infusion rate (GIRmax) and time to GIRmax (GIR-Tmax)

    Time frame: 36 hours

  8. Duration of blood glucose control (time to elevation of smoothed blood glucose profile above different pre-specific blood glucose levels)

    Time frame: 4 days

  9. Safety and tolerability (Number of patients with adverse events, clinically significant changes in vital signs, laboratory parameters)

    Time frame: 4 days

07

Study locations

1 site
  • Investigational Site Number 276001
    Neuss, 41460, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2014
First posted
Jul 25, 2014
Start
Aug 2014
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
Dec 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02201199
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 25, 2014
Start date
Aug 2014
Primary completion
Nov 2014
Completion
Nov 2014
Last update
Dec 24, 2014

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion